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Abstract: 
Ischaemia Reperfusion (IR) injury is a major cause of post-operative morbidity, 
mortality and graft loss following Orthotopic Liver Trasnplantation (OLT). There is 
no current accepted treatment for IR injury. The recent drive to implant more 
marginal grafts, which are more susceptible to IR injury makes this clinical problem a 
key research goal. Remote Ischaemic Preconditioning (RIPC) has been shown to 
ameliorate hepatic IR injury in small animal models. Whether recipient RIPC can 
reduce IR injury in human liver transplant recipients has not previously been 
investigated. 
Methods: 
Forty patients with end stage liver disease undergoing liver transplantation were 
randomized to RIPC or a sham control group. RIPC was induced through three 5 
minute cycles of alternate ischaemia and reperfusion using an orthopaedic tourniquet 
to the left lower limb under general anaesthesia prior to commencement of the 
abdominal procedure. The aim of the study was to determine the safety and feasibility 
of limb RIPC in patients with end stage cirrhosis. Data on clinical outcomes was 
collected prospectively (minimum 3 month follow up) and the function of the graft 
was also evaluated. Plasma cytokine levels were measured at baseline, 2 hours post 
reperfusion and at 24 hours post-operatively. 
Results: 
45 of 51 patients approached (88%) were willing to enroll in the study. 5 patients 
were then excluded and 40 patients were randomized of which 20 underwent RIPC. 
RIPC was able to be performed in all patients randomized to the RIPC group. There 
was no evidence of localized complications following RIPC. One patient died in the 
control group and 1 further graft was lost in the control group due to a non-IR related 
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issue. Median AST levels on the third post-operative day showed a slightly higher 
trend in the RIPC group than in the control group (221iU vs 149iU, p=1.00) but this 
was not statistically significant. 
 
Conclusions: 
RIPC is acceptable and can be carried out safely in patients with advanced liver 
disease. This pilot feasibility study has not demonstrated evidence of a reduction in IR 
injury or clinical benefit. A longer follow up, a larger study or an altered 
preconditioning protocol may be required. 
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Liver transplantation is the treatment of choice for both acute and chronic end stage 
liver disease. As outcomes following transplantation have improved, the indications 
for liver transplantation have been widened and a shortage of suitable organ donors 
has developed. This has resulted in an increased use of grafts from marginal donors 
such as the elderly and those with a fatty liver from obesity (extended criteria donors) 
and especially the use of grafts from donors following cardiac death (DCD). The use 
of liver DCD grafts in the UK has increased from 6.9% in 2005
1
 to 19.1% of grafts 
implanted in 2013
2
. 
Ischaemia Reperfusion (IR) injury is the damage that happens to an organ when its 
blood supply is interrupted and reconstituted. It is a major cause of morbidity and 
mortality following liver transplantation and is believed to account for up to 10% of 
early graft loss
3
. 
Grafts from extended criteria donors are particularly prone to IR injury and in UK 
centres, the implantation of DCD grafts is associated with a 2 fold increase in risk of 
graft loss and recipient mortality which is maintained for 3 years post transplantation
1
. 
Due to this increased susceptibility to IR injury and the poor clinical outcome, grafts 
from extended criteria donors are often discarded. The ability to ameliorate IR injury 
would therefore improve outcome following liver transplantation, reduce early graft 
loss and the need for re-transplantation and would allow the safe implantation of more 
marginal grafts increasing the potential donor organ pool. There is no current 
accepted treatment for IR injury and as such the development of strategies to treat IR 
injury remains a key clinical concern in the field of solid organ transplantation. 
Ischaemic Preconditioning (IPC), first described in a canine cardiac model
4
, is the 
process by which short periods of ischaemia to the target organ  protect that organ 
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during further more substantial periods of ischaemia. Despite robust evidence of the 
protective benefit of direct IPC in small animal models
5,6
, direct IPC has been shown 
in small animal models to impair liver regeneration
7, 8
. Although this effect has not 
been shown on donor grafts in human liver transplantation, a multivariate analysis has 
shown that direct IPC is an independent predictor for post-operative morbidity
9
 
following hepatic resection surgery in humans. 
Ten small studies have investigated the effect of direct IPC of donor livers in the 
setting of deceased donor liver transplantation and a recent meta-analysis has shown 
that donor IPC of donor grafts lead to a large reduction in recipient mortality and 
incidence of primary graft non-function although this difference was not statistically 
significant
10
. 
Remote Ischaemic Preconditioning (RIPC), again first described in a canine cardiac 
model
11
, is the process by which preconditioning of one organ or vascular bed 
provides protection to distant organs or vascular beds during a sustained period of 
ischaemia. RIPC has been shown by our own group and others to ameliorate hepatic 
IR injury in small animal models
12, 13, 14, 15
. It has also been translated into clinical 
benefit in patients undergoing both cardiac surgery
16
 and major vascular surgery
17
. In 
major liver surgery, RIPC was shown in a pilot RCT to reduce liver IR injury as 
indicated by a reduction in post operative transaminases and increased ICG clearance. 
Successful use of RIPC in liver transplant recipients would avoid the complexity of 
organizing and the ethics of preconditioning at the multiple donor sites and the 
potential risk of impairing graft regeneration following implantation.  
Although the mechanism by which RIPC and IPC protect organs from IR injury 
remain unknown, the process of performing RIPC in the recipient more closely 
resembles successful animal models in which preconditioning is performed in the 
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individual in which the reperfusion injury occurs and therefore may be more 
efficacious than IPC of donor livers
18
. RIPC of renal transplant recipients has been 
investigated in 2 recent trials including both living
19
 and deceased
20
 donors with 1 
trial demonstrating an improvement in early graft function
20
. No trial as yet has 
investigated RIPC in liver transplant recipients and there are therefore fundamental 
issues which have to be addressed. These include the willingness of patients, their 
clinicians and the transplant anaesthetists to support such a trial. Patients undergoing 
liver transplantation mainly have end stage cirrhosis and the risk of limb conditioning 
in patients with jaundice and a coagulopathy are unknown. Finally the conditioning 
protocol which has been used in other clinical applications may not be optimal with 
the altered metabolism and haemodynamics of end stage liver disease?cirrhosis. 
 
The aims of this study was to perform a prospective randomized controlled feasibility 
study to address these issues and to obtain preliminary data on which to design a 
further prospective trial to determine efficacy and cost effectiveness. 
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Methods: 
A single centre double blinded open prospective randomised controlled trial was 
performed at the Royal Free Hospital following approval by the NHS National 
Research Ethics Service (11/H0720/4) and the Royal Free Hospital/University 
College London medical school ethical committee (8191). The trial involved 
randomization of adult recipients undergoing deceased donor liver transplantation and 
was registered with ClinicalTrials.gov: Number NCT00796588. The protocol has 
been previously published
21
. 
Patients above the age of 18 undergoing first elective deceased donor liver 
transplantation were enrolled with informed consent in the study for randomization. 
All graft types were included. Exclusion criteria are contained in Table 1. 
 
51 patients were approached for recruitment to the study of which 6 patients were 
unwilling to recruit to the trial and 5 patients were excluded. 40 patients were 
randomized to a sham control group and a RIPC group. Randomisation was 
performed, following induction of anaesthesia, using a sealed envelope method by the 
study fellow who was not involved with the transplant surgery or post operative care 
(CONSORT flowchart, Figure 1). 
Both patients and clinical teams, including the transplant surgeon, were blinded as to 
which group the patient was randomized to. 
 
Endpoints: 
The primary endpoints were: 
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1: Feasibility to recruit patients with end stage cirrhosis to undergo limb 
preconditioning prior to commencement of liver transplantation. 
2: Investigate the safety of limb pre-conditioning in patients with end stage cirrhosis. 
This included the assessment of any clinical evidence of a deep vein thrombosis or 
pulmonary embolus, the development of localized cellulitis and pain or paresthesia of 
the left lower limb following RIPC and subsequent surgery. Secondary endpoints are 
listed in Table 2 and include mortliaty, morbidity as measured using Clavien Dindo 
classification, graft function assessed using day 3 aspartate transferase (AST) levels
22
 
and early allograft dysfunction (EAD) as defined by Olfthoff et al
23
. 
Donor organ and patient demographics were recorded as …..? 
The preconditioning stimulus: 
Following induction of anaesthesia but before skin incision, the left lower limb was 
covered with 2 layers of stockinette and a wide pneumatic tourniquet was applied to 
the left middle thigh in accordance with safe and recommended practices by the 
Association of Peri-operative Registered Nurses (AORN)
24
. To induce RIPC through 
transient ischaemia, the tourniquet was inflated to 200mmHg for 5 minutes and then 
deflated for 5 minutes to reperfuse the leg. This was repeated 2 more times and 
completed prior to the abdominal incision for the transplant procedure. The control 
group had placement of the tourniquet, which was not inflated? 
 
Liver transplantation: 
Grafts were identified and retrieved through the dedicated UK National Organ 
Retrieval Service (NORS) according to national standards of organ retrieval from 
deceased donors
25
 (NHSBT). All grafts were perfused in situ and transported in cold 
University of Wisconsin (UW) solution (Organ Recovery Systems, Chicago) at a 
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maximum pressure of 200mmHg following aortic cannulation. The liver graft was 
further flushed with ice cold UW solution on the back bench via the hepatic artery, 
portal vein and the bile duct once retrieved and transported in cold storage. Grafts 
which were stored and transported using normothermic perfusion using the OrganOx 
system as part of a contemporaneous trial were excluded from this study.  
All patients were monitored intra-operatively via invasive central arterial and venous 
catheters Implantation of the liver graft was performed by standard piggy-back and 
caval replacement techniques. Veno-venous bypass was not employed in any patient 
randomsied in this trial. Grafts were flushed with 500-1000mls warm 4.5% human 
albumin solution (Bio Products Laboratory) via the portal vein following implantation 
of the graft and immediately prior to blood re-perfusion to remove residual UW 
solution and waste material accumulated during cold ischaemia. 1g of 
methylprednisolone (Pharmacia) was given intravenously during the anhepatic phase 
as part of standard anaesthetic protocol. 
 
Post operative management: 
Post-operatively all patients were managed in the intensive care unit. 
Haemoglobin levels were maintained below 10g/L to reduce the risk of graft 
thrombosis. 
Platelets and fresh frozen plasma were not administered unless there was active 
bleeding post operatively resulting in cardiovascular compromise or abdominal 
compartment syndrome. Patients were routinely started on subcutaneous 
thromboprophylaxis on the first post operative day. 
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All patients underwent a Doppler ultrasound scan of the liver vessels on the first, third 
and fifth post-operative day and daily bloods including coagulation profiles and serum 
transaminases. 
Patients were extubated on the first post-operative day unless there was a clinical need 
for ongoing respiratory support and triple therapy immunosuppression was 
commenced on day 1 post-operatively. If there was evidence of early renal 
impairment, monoclonal antibody therapy was given in place of triple therapy 
immunosuppression. 
 
Measurement of cytokines: 
In both groups, 10mls of peripheral arterial blood was collected at the following time 
intervals: 
 baseline (following induction of anaesthesia), before knife to skin? 
 immediately before the recipient’s portal vein and cava were cross clamped, 
 2 hours post reperfusion of the portal vein, 
 24 hours post-operatively. 
Blood was collected in BD vacutainer plasma tubes (BD, UK). Samples were 
immediately centrifuged at 1000g for ten minutes and the plasma was stored at -80
0
C 
until analysis. IL2, IL6, IL10, TNF and IFN were measured by legendPLEX 
(Biolegend, UK)- Human Th Cytokine Mix and Match Subpanel. IL8 (Biolegend, 
UK) and IL17A (Biolegend, UK) were measured by ELISA via commercial kits. 
 
Oxygenation levels during preconditioning:  
Two 2mls bloods samples were collected simultaneously. A venous blood sample was 
collected from the recipients left foot in lithium heparin gas syringes (BD Preset, 
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UK), after 4.5 minutes of lower limb vascular occlusion while the tourniquet was still 
inflated or at the same time point in the sham group. A simultaneous peripheral 
arterial blood sample was collected from the arterial line and identically managed. 
Oxygen levels, lactate levels and acid base status were measured instantly from both 
samples on a RAPIDPoint 500 blood gas analyser (Siemens, Surrey, UK). 
 
Statistical analysis and power calculation: 
A power calculation is not required for a pilot feasibility study
26
 however guidance 
would suggest that 40 patients would be suitable for a feasibility study
27
 with 20 
patients randomized to RIPC and 20 patients randomized to a sham. 
Continuous variables were expressed as median (+ inter-quartile range) or mean (± 
standard deviation) as appropriate and comparisons between the groups were analysed 
by Mann Whitney-U test or Students’ T-Test as appropriate. Binary outcomes were 
expressed as frequency counts and percentages and comparisons between the groups 
were analysed by Chi-squared tests on Statistical Package for Social Sciences (SPSS) 
(IBM, Chicago, IL, USA) and Prism 5 (Graphpad, USA). 
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Results: 
Feasibility and recruitment: 
Fifty–one patients were approached of which 45 (88%) were willing to enroll in the 
trial. Five patients were subsequently excluded due to concern regarding possible risk 
from intermittent limb ischaemia from the tourniquet. Four of the five patients had a 
prior history of thromboembolic disease and 1 patient had varicose veins of the left 
lower limb. The remaining 40 patients were randomized with 20 randomized to RIPC 
and 20 to a sham control. The patients were well matched at baseline. The 
characteristics of the recipients and donors are shown in Tables 3 and 4. 
All patients randomized to undergo preconditioning were successfully preconditioned 
prior to abdominal incision. There was no evidence of haemodynamic instability or 
vagal response either during the cuff inflation or after reperfusion of the limb. Visual 
inspection of the limb following preconditioning showed no evidence of 
bruising/haematoma formation. 
No patient complained of pain or parasthesia post-operatively. There was no clinical 
evidence of DVT or PE formation in any patient.  
 
Secondary end-points: 
1: 90 day graft and patient survival 
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One patient in the control group died peri-operatively as a result of significant intra-
operative haemorrhage and primary graft non-function (PGNF). There was no 90 day 
mortality in the RIPC group. One patient in the control group required 
retransplantation on the 4
th
 post-operative day following the discovery of an 
incidental adeno-carcinoma in the donor’s gallbladder.  
 
2: Complications: 
There were no significant differences in incidences of post-operative complications 
between the groups (Table 5) including infective complications and incidence of AKI. 
3: Graft function: 
Aspartate transferase levels on the 3
rd
 post operative day were trending to be higher in 
the preconditioning group but this did not reach significance (221iU (82-434) vs 
149iU (103-370), p=1.00). There was a also a trend to higher incidence of EAD in the 
preconditioned group but this was not significant (10 vs 7, p=0.523). Although 
median transaminase levels, in the first week post transplantation, were higher in 
recipients that underwent RIPC, median bilirubin (27μmol/L (19-37) vs 41μmol/L 
(23-74), p=0.087) and alkaline phosphatase levels (215iU/L (168-293) vs 275iU/L 
(218-351), p=0.126), at day 7 post transplantation, were trending to be lower in 
recipients who were preconditioned although this was not statistically significant. By 
3 months post transplant both groups were similar in all measured indices. 
4: Acute cellular rejection: 
Incidence of acute cellular rejection was low with only one episode proven by biopsy 
in the control group and no episodes in the preconditioning group. 
5: ITU and total hospital stay: 
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Patients in the preconditioning group spent longer in ITU post operatively (4 days vs 
3 days, p=0.372) and in hospital post transplantation (20 days vs 16 days, p=0.409), 
although this was not statistically significant. 
 
Limb oxygenation during RIPC: 
Arterial oxygen levels measured from the radial artery during the preconditioning 
stimulus were similar between the preconditioned and control groups 
(28.87(±9.73)kPa vs 30.43(±12.63)kPa, p=0.757). Venous oxygen levels measured at 
the same time in the lower limb during the preconditioning stimulus were 
significantly lower in the preconditioning group than the control group (7.53(4.94-
9.28)kPa  vs 15.06(8.67-19.00)kPa, p=0.004) however the venous pO2 levels do not 
support the creation of localized ischaemia during RIPC (figure 2). 
 
Plasma cytokine levels: 
Plasma levels of IL6, IL8, IL10 and IL17a were significantly raised from baseline at 2 
hours post reperfusion and had returned to near baseline levels within 24 hours 
(Figure 3). Plasma levels of IL2, IFN-γ and TNF-α did not change during the peri-
transplant period (Table 6). The median IL-6 levels in the preconditioned group were 
significantly lower than in the control group (487.99 (221.65-1232.37)pg/ml vs1062.3 
(221.5-25903.85)pg/ml, p=0.013) (figure 4). Median levels of all other cytokines 
measured were similar between both groups and are shown in figure 4. 
There was no significant difference in post reperfusion levels of Il-6, IL8, IL10 and 
IL17a in patients that went on to develop early allograft dysfunction, an infective 
complication post-operatively or the need for prolonged organ support. 
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Discussion: 
This is the first trial to prospectively investigate RIPC of liver transplant recipients as 
far as we are aware . It has demonstrated that RIPC is feasible, acceptable to patients  
and safe to perform in liver transplant recipients. 
Recruitment to the trial was satisfactory with a consent rate of 88% and a post 
randomization drop out of 0%. RIPC was successfully completed in all patients. No 
patient suffered a complication secondary to RIPC and in no patient was surgery 
delayed as result of undergoing RIPC. This study satisfied the primary objectives of 
the feasibility study
21
. 
Ninety day mortality and graft loss was low in this cohort of patients with one peri-
operative death and only one other graft loss within the study period. It is therefore 
unsurprising that RIPC was unable to demonstrate any benefit by a reduction in 90 
day morbidity and mortality in this small population of patients. 
In UK centres, current 90 day graft loss and patient mortality following elective liver 
transplantation is 3.5% and 6.9% respectively
28
 and as such designing a trial based on 
these end-points would be difficult due to the required recruitment rate necessary to 
demonstrate a significant improvement by one intervention. Further secondary end-
 16 
points were therefore chosen as they may identify more subtle differences in 
outcomes post transplantation and aid the design of a future cost-effectiveness study. 
Common post operative complications were documented including infective 
complications and post operative organ dysfunction as these would indicate a poorly 
functioning graft. Patients who underwent preconditioning had a higher incidence of 
post operative acute kidney injury (9 vs 7) and need for renal replacement therapy (5 
vs 3). The mean days ventilated post operatively was similar between the 2 groups (2 
vs 2). Severe IR injury results in a systemic inflammatory response and end organ 
damage. AKI is a particular problem post AKI and documented rates in the literature 
range from 14% to 94%
29–34
. A recent audit of incidence of AKI at the Royal Free 
Hospital found that AKI occurs in around 50% of patients undergoing liver 
transplantation. Sixteen patients (40%) of patients developed an AKI so this is 
representative of our general patient cohort. These data would suggest that RIPC did 
not reduce the incidence of end organ dysfunction following IR injury. 
In such a small pilot study that was not powered to detect a significant difference in 
mortality and graft loss, surrogate markers were assessed. Graft function including 
AST levels on the 3
rd
 post-operative day (which have been shown to correlate 
strongly with both graft survival and recipient outcomes
22
 ) and EAD (which has also 
been shown to be associated with an increased risk of graft loss and recipient 
mortality
23
 ) were both measured. Median AST levels on day 3 were non-significantly 
higher than in the control group again suggesting that in its current form RIPC has not 
reduced IR injury in the liver graft and is not associated with an improvement in graft 
or recipient outcome. This is further reflected by a non-statistically significant higher 
incidence of EAD in the RIPC group (50% vs 37%, p=0.523). It should however be 
noted that patients who underwent RIPC had a non significant reduction in bilirubin 
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levels (27mol/L vs 41mol/L, p=0.087) at day 7 contrarily suggesting evidence of 
better early graft function. 
Taken together this data shows that although RIPC is safe and feasible to be 
performed in patients undergoing liver transplantation, in its current form it does not 
provide evidence of clinical benefit to liver transplant recipients in this small patient 
group.  
Results from previous studies of RIPC have been conflicting. Despite initial success 
in children undergoing cardiac surgery
16
 and promising results from a phase II trial
35
, 
a recent large randomized trial of RIPC in cardiac surgery has failed to shown any 
significant benefit gained from RIPC
36
. In the setting of clinical transplantation 2 
trials of RIPC have been performed. The results however are conflicting with 1 trial 
demonstrating evidence of improved early graft function
20
 whist 1 trial failed to 
demonstrate any improvement in graft function or a reduction in early biomarkers
19
.  
 
It is unclear from the published manuscripts whether or not supplementary oxygen 
was administered to the patients in these trials during the pre- or intraoperative period. 
In this study we investigated the degree of hypoxia which was achieved using the 
pneumatic cuff. One important finding from our study was that although the venous 
pO2 in the limb was significantly lower in patients undergoing RIPC compared with 
controls, true hypoxia was not achieved in the limb during the preconditioning 
stimulus as assessed by ……. There could be several reasons for this,  including 
errors in cuff inflation. However the standard deviation of the venous pO2 levels is 
small (6.19kPa) suggesting that this is not the case. It may be that the high FiO2 
delivered to the patients during the transplant procedure, including  during the period 
of preconditioning stimulus,  prevented significant tissue hypoxia in the conditioned 
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limb. This would suggest that 5 minutes of tourniquet inflation was insufficient to 
create localized ischaemia in the limb in these patients. This mirrors the results from 
direct preconditioning of liver grafts in donors prior to organ retrieval in which 5 
minutes of ischaemia was found not to be of any benefit
37
 but 10 minutes of 
ischaemia was shown to provide a degree of protection  demonstrated by a reduction 
in markers of liver injury
38
. The optimal protocol for RIPC in humans remains to be 
established. A pilot study of RIPC in patients undergoing liver resection using 10 
minute cycles to perform the preconditioning stimulus showed evidence of a 
reduction in liver injury as demonstrated by a reduction in post operative 
transaminases and improve ICG clearance and as such a further trial with 10 minute 
cycles is warranted. 
 
It is widely accepted that IR injury results in systemic cytokine release and activation 
of the systemic response syndrome with resulting end-organ damage
39, 40. TNFα, is a 
key cytokine shown to be upregulated early following IR injury and to promote 
recruitment of lymphocytes to the ischaemic injury
41
. Other cytokines that have been 
implicated in IR injury in small animal models include IL-2
42
, IL-6
43
, IL8
44
, IL-17
45
 
and IFNγ43 and these were measured in this study. A previous observational study in 
humans undergoing liver transplantation
46
 measured circulating serum cytokine levels 
at 24 hours post transplantation and found that the in the majority of patients, 
circulating levels were below the detectable level especially IFNγ (99%) and TNFα 
(77%). These results are similar to our results which show that systemic cytokine 
levels were below the detectable levels in the majority of patients at 24 hours post 
reperfusion. Although 17 patients developed an AKI as measured by the AKIN 
criteria – suggesting a systemic inflammatory response and end organ damage, 
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plasma levels of IL2, IFNγ and TNFα were not significantly raised from base line in 
our patients even 2 hours post reperfusion suggesting that these cytokines may not be 
involved in the systemic inflammatory response post transplant. This is in keeping 
with results from canine lung IR injury which showed no elevation in serum IL-2, 
IFNγ and TNFα although they were significantly elevated in bronchial alveolar lavage 
samples
47
 showing they may be involved in the local inflammatory response. 
In the current study, circulating levels of IL-6, IL-8, IL-17A and IL-10 were elevated 
at 2 hours post reperfusion and were similar to baseline levels by 24 hours. Similar 
peaks of circulating levels of IL-6 and Il-8 were seen in patients at 2 hours post liver 
resection
48
 however circulating levels remained elevated at 24 hours post operatively 
in comparison to this study when levels returned to near baseline. This may reflect the 
fact that post liver transplant patients are immunosuppressed whilst they are not 
following liver resection surgery. Similarly the peak of plasma Il-10 levels at 2 hours 
in our patients likely represents the anti inflammatory effect of the intravenous dose 
of methylprednisolone given during the anhepatic phase of the transplant. In this 
study there were significantly lower levels of circulating IL-6 in patients who 
underwent RIPC. However the significance of this result is unclear. Plasma IL-6 
levels post reperfusion showed a positive correlation with the calculated donor risk 
index
49
 suggesting that IL-6 levels vary with the quality of donor organ. Higher IL-6 
levels post liver resection have been shown to be associated with increased risk of 
post-operative complications and bile leaks
48
. However plasma IL-6 levels were not 
higher in patients who developed either EAD or AKI which are associated with poor 
quality grafts. Furthermore although patients undergoing RIPC had lower levels of 
IL-6 post reperfusion, there was no evidence that this was associated with a reduction 
in graft injury or an improvement in clinical outcomes. 
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In conclusion, to our knowledge, this is the first trial to investigate RIPC of liver 
transplant recipients and has shown that RIPC is feasible and safe in liver transplant 
recipients. In its current form it does not appear to provide any clinical benefit 
detectable within the first 3 months post transplantation. Venous blood gas 
measurements taking from the limb during the preconditioning period suggest that 5 
minute cycles are insufficient to create localized ischaemia in the limb. 
We would suggest that a pilot RCT of RIPC vs sham with an altered preconditioning 
protocol for example of three 10 minute cycles is evaluated prior to considering a 
larger scale study aimed a determining efficacy and cost effectiveness. 
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Table 1: Exclusion Criteria 
Exclusion criteria: 
Re-transplantation 
 
Patients under 16 years of age 
 
Super-urgent transplantation 
 
Lack of informed consent 
 
Combined liver and kidney transplantation 
 
Peripheral vascular disease 
 
Varicose veins 
 
Localized limb infection 
 
Prior history of thrombo-embolic disease 
 
Inclusion in another interventional trial 
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Table 2: Primary and secondary trial endpoints. 
Primary endpoints: 
Ability to recruit patients to the trial 
 
Feasibility of performing RIPC in liver transplant recipients 
 
Safety of RIPC in liver transplant recipients 
 
 90 day recipient mortality 
 90 day graft loss 
Secondary endpoints: 
AST levels on the third post-operative day
22
 
 
Incidence of Acute Kidney injury and need for Renal 
Replacement therapy 
 
Length of stay in Intensive Care and total hospital stay 
 
Incidence of vascular thrombotic events 
 
Incidence of biliary complications 
 
Incidence of post-operative infections 
 
Incidence of acute rejection in the first months post 
 29 
transplantation 
 
Circulating cytokine levels 2 hours post reperfusion of the 
liver graft 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Base-line recipient characteristics (mean ± SD). 
Recipient characteristics RIPC Control P vaue 
Gender (M:F) 18:2 16:4 0.661 
Age 55 (±10) 54 (±9) 0.758 
MELD 15 (±5) 13 (±5) 0.190 
UKELD 55 (±5) 52 (±5) 0.085 
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Table 4: Baseline donor and Transplant characteristics (mean ± SD) 
Donor  and Transplant characteristics RIPC Control P value 
Gender (M:F) 16:4 13:7 0.731 
Age 43 (±14) 47 (±16) 0.376 
Type of graft    0.723 
     DBD 15 17  
     DCD 3 2  
     Domino 1 0  
     Split 1 1  
Cold ischaemic time (mins) 470 (±140) 455 (±157) 0.750 
Warm ischaemic time (mins) 44 (±14) 42 (±11) 0.546 
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Table 5: Clinical outcomes in RIPC and control groups 
 RIPC Control P value 
3 month mortality 0 1 1.00 
3 month graft loss 0 2 0.487 
Day 3 AST 221 (82-434) 149 (103-370) 1.00 
EAD 10 7 0.523 
Mean ITU stay (days) 4 (±2) 3 (±3) 0.372 
Mean days ventilated 2 (±1) 2 (±1) 0.758 
Need for RRT 5 3 0.695 
Portal vein thrombosis 0 0 1.00 
Hepatic artery thrombosis 0 0 1.00 
Biliary stenosis 2 1 0.501 
Bile leak 1 2 0.459 
Bacteraemia 3 2 0.549 
Chest infection 0 1 0.349 
Abdominal infection 3 2 0.549 
Wound infection 4 7 0.303 
Urine infection 2 3 0.517 
Mean hospital stay (days) 31 (±46) 21 (±14) 0.409 
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Table 6: Plasma cytokine levels during the transplant period (Median + IQR) * denotes 
significance identified with Kruskal-Wallis. 
Cytokine Baseline (pg/ml) Pre implantation (pg/ml) Post reperfusion (pg/ml) 24 hours post-op (pg/ml) 
IL-2 9.34 (4.08-35.11) 7.50 (4.08-40.40) 6.19 (4.08-17.13) 12.16 (4.08-42.29) 
IL-6* 13.98 (8.27-44.80) 245 (150.97-375.12) 644.98 (338.31-1132.01) 21.58 (10.11-43.29) 
IL-8* 0.88 (0-3.26) 8.23 (1.28-15.84) 30.59 (15.37-52.42) 0.88 (0-3.11) 
IL-10* 4.22 (3.72-7.69) 9.83 (4.38-16.96) 540.74 (344.21-815.48) 7.37 94.56-35.26) 
IL-17A* 2.14 (1.74-2.96) 2.40 (1.68-3.2) 2.94 (1.85-8.78) 1.86 (0.81-2.33) 
IFNγ 57.13 (18.05-176.09) 32.66 (17.15-73.29) 31.41 (10.92-107.48) 17.35 (6.50-44.20) 
TNFα 7.97 (3.5-53.16) 7.17 (3.5-33.79) 7.15 (5.46-8.58) 6.46 (3.5-8.58) 
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Figure 1: CONSORT flow diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n= 51) 
Excluded  (n= 11) 
   Not meeting inclusion criteria (n= 0) 
   Declined to participate (n= 6) 
   History of PVD (4), TED (1) 
Allocated to intervention (n= 20) 
 Received allocated intervention (n= 20) 
 Did not receive allocated intervention (n= 0) 
Allocated to control (n= 20) 
 Received allocated control (n= 20) 
 
Allocation 
Follow-Up 
Randomized (n= 40) 
Enrollment 
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Figure 2: Venous oxygen levels in the limb during the preconditioning cycle. 
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Figure 3: Circulating cytokine levels that showed a significant increase during liver 
transplant and at 24 hours post op. 
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Figure A (IL-6) and Figure B (IL-8) demonstrate a significant increase in 
circulating cytokine levels following mobilization of the recipient liver but prior 
to hepatectomy and a further significant increase in cytokine levels at 2 hours 
post reperfusion. Levels returned to near baseline levels at 24 hours post 
operatively.  
Figure C (IL-10) and Figure D (IL-17A) demonstrate significantly elevated 
cytokine levels at 2 hours post reperfusion only. 
 
 
 
 
 
 
 
 
Figure 4: Circulating cytokine levels between the groups. 
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Only IL-6 levels (Figure A) were significantly reduced in patients undergoing 
RIPC. 
